Conformal Sealant for Burn Wound Repair
用于修复烧伤创面的敷形密封剂
基本信息
- 批准号:7793722
- 负责人:
- 金额:$ 18.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-30 至 2012-09-29
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAddressAdmission activityAnti-Bacterial AgentsAntibioticsBacitracinBiocompatibleBurn injuryCaringChildCicatrixContractureCreamDermalDermisDrug FormulationsEstheticsFamily suidaeGoalsHealedHospitalsHydrogelsIn VitroInfection preventionInjuryIntentionMedical centerModelingOcclusive DressingsPatientsPropertyRecommendationSepsisSideSpeedSterile coveringsTestingTextThickTimeTissuesTopical AntibioticValidationVisitWound Healingage groupbactericidebasebiomaterial compatibilitycell typecytotoxicityfunctional disabilityhealingimprovedin vivomortalitypublic health relevancesealstandard carestatisticsvalidation studieswound
项目摘要
DESCRIPTION (provided by applicant): Deep partial thickness burns involve the deeper layers of the dermis, and usually do not heal for at least 2 to 3 weeks. This often results in significant scarring and contractures, especially in children. There is no established standard treatment for deep partial thickness burns. In general, they may be covered with an occlusive dressing or a topical antimicrobial (e.g., Silvadene or bacitracin) cream and an absorptive dressing; evidently, these are all applied on an ad hoc basis and none of them promotes healing. The unmet challenge of burn treatment is to devise a remedy that prevents infection, speeds healing and reduces scarring. In this project, we will formulate a formable/conformable antibacterial tissue sealant dressing specific for treating burn wounds. In parallel, we will validate the lack of cytotoxicity potential of each tissue sealant formulation using model cell types that the hydrogel will most likely be in close contact upon deployment, to be followed by in vivo biocompatibility testing. The anti-bacterial activities will also be tested, to be followed by an in vivo efficacy validation study in porcine dermal burns.
PUBLIC HEALTH RELEVANCE: Burns are one of the most common causes of injury in all age groups. The primary goals of acute burn wound management are prevention of infection and the promotion of optimal wound closure by re-epithelialization to minimize aesthetic and functional impairment. Deep partial thickness burns involve the deeper layers of the dermis, and usually do not heal for at least 2 to 3 weeks. This often results in significant scarring and contractures, especially in children. There is no established standard treatment for deep partial thickness burns. In general, these burns may be covered with an occlusive dressing or a topical antimicrobial (e.g., Silvadene or bacitracin) cream and an absorptive dressing; evidently, these are all applied on an ad hoc basis and none of them promotes healing. The unmet challenge of burn treatment is to devise a remedy that prevents infection, speeds healing and reduces scarring. It is our intention to develop an antibacterial tissue sealant capable of sealing the burn wound, preventing infection, accelerating wound healing and reducing scarring.
描述(申请人提供):深度部分烧伤累及真皮较深层,通常至少2至3周内不会愈合。这往往会导致严重的疤痕和痉挛,特别是在儿童中。深度烧伤的标准治疗方法尚无定论。一般来说,可以用封闭敷料或局部抗菌(如西瓦丁或杆菌肽)乳膏和吸收敷料覆盖它们;显然,这些都是临时应用的,它们都不能促进愈合。烧伤治疗尚未解决的挑战是设计一种预防感染、加速愈合和减少疤痕的药物。在本项目中,我们将研制一种用于治疗烧伤创面的可成形/可适应抗菌组织密封剂敷料。同时,我们将使用水凝胶在部署时最有可能密切接触的模型细胞类型来验证每种组织密封剂配方是否缺乏细胞毒性潜力,然后进行体内生物兼容性测试。还将测试其抗菌活性,随后将进行猪皮肤烧伤的体内疗效验证研究。
公共卫生相关性:烧伤是所有年龄段最常见的伤害原因之一。急性烧伤创面处理的主要目标是预防感染和通过再上皮化促进创面的最佳闭合,以最大限度地减少美学和功能损害。深度部分烧伤累及真皮较深层,通常至少2至3周内不会愈合。这往往会导致严重的疤痕和痉挛,特别是在儿童中。深度烧伤的标准治疗方法尚无定论。一般来说,这些烧伤可以用封闭敷料或局部抗菌(如西尔瓦丁或杆菌肽)乳膏和吸收敷料覆盖;显然,这些都是临时使用的,都不能促进愈合。烧伤治疗尚未解决的挑战是设计一种预防感染、加速愈合和减少疤痕的药物。我们的目的是开发一种能够封闭烧伤创面、防止感染、加速创面愈合和减少瘢痕形成的抗菌组织密封剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Weiliam Chen其他文献
Weiliam Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Weiliam Chen', 18)}}的其他基金
Preventing Post-Laminectomy Peridural Fibrosis
预防椎板切除术后硬膜外纤维化
- 批准号:
7534544 - 财政年份:2008
- 资助金额:
$ 18.52万 - 项目类别:
In Situ Gelable Filler for Obliteration of Cerebral Aneurysm
原位凝胶填充剂用于闭塞脑动脉瘤
- 批准号:
7273992 - 财政年份:2007
- 资助金额:
$ 18.52万 - 项目类别:
Polysaccharide Hydrogel Fillers for Arteriovenous Malformation
多糖水凝胶填充剂治疗动静脉畸形
- 批准号:
7325832 - 财政年份:2007
- 资助金额:
$ 18.52万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 18.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 18.52万 - 项目类别:
Operating Grants














{{item.name}}会员




